2023

Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective

A.L. Moura al-moura@hotmail.com¹, C. Pereira^1,2, F.S. Regateiro^1,3, J. Azevedo¹, A. Todo Bom^1,4, I. Carrapatoso¹

Vol. 51 (No. 5) 2019 September

Original Article

doi: 10.23822/EurAnnACI.1764-1489.99

Show more: Authors information and Publication history

Authors Information

¹Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
²Clinical Immunology, Faculty of Medicine, University of Coimbra, Portugal
³Institute of Immunology, Faculty of Medicine, University of Coimbra, Portugal
⁴Faculty of Medicine, University of Coimbra, Portugal

History

Published online: 08 July 2019
Accepted: 29 April 2019
Received: 23 January 2019

SUMMARY

KEY WORDS

LTP syndrome; peach allergy; Pru p 3; sublingual immunotherapy; ultra-rush protocol

Full text PDF

Table of Content: Vol. 51 (No. 5) 2019 September

Review

Metabolic interactions in asthma

M. Farraia mariana.farraia@gmail.com ^1,2, J. Cavaleiro Rufo¹, I. Paciência^1,2,3, F. Castro Mendes², L. Delgado^4,5, J. Laerte Boechat⁶, A. Moreira^1,2,7

doi: 10.23822/EurAnnACI.1764-1489.101

Download PDF

Letter to the Editor

Availability of epinephrine auto-injectors and knowledge of community pharmacists about their use

C. Pitsios pitsios.constantinos@ucy.ac.cy, A. Vasiliadis, K.P. Karakatsanis, R. Matzaras, T. Minasidis, A. Nteveros, G. Samanis, G. Nikolopoulos

doi: 10.23822/EurAnnACI.1764-1489.106

Download PDF

Original Article

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

J. Cuesta-Herranz¹, J.J. Laguna², R. Mielgo³, I. Pérez-Camo⁴, A.M. Callejo⁵, L. Begoña leire.begona@roxall.es ⁶, M.C. Gomez⁶, B. Madariaga⁶, A. Martinez⁶

doi: 10.23822/EurAnnACI.1764-1489.104

Download PDF

Original Article

Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study

M. Kurosawa motohiro@kl.wind.ne.jp ¹, K. Ogawa², E. Sutoh^1,2

doi: 10.23822/EurAnnACI.1764-1489.94

Download PDF

Original Article